Emergent BioSolutions Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2021-02-08

Reporting Person: Kramer Robert (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-08	Common Stock	M	32397	$30.86	Acquired	171607	Direct
2021-02-08	Common Stock	S	32397	$120.03	Disposed	139210	Direct
2021-02-08	Common Stock	M	13000	$30.63	Acquired	152210	Direct
2021-02-08	Common Stock	S	13000	$120.03	Disposed	139210	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-08	Employee Stock Options (Right to Buy)	$30.86	M	32397	Disposed	2023-02-28	Common Stock (32397.0)	Direct
2021-02-08	Employee Stock Options (Right to Buy)	$30.63	M	13000	Disposed	2024-02-27	Common Stock (13000.0)	Direct

Footnotes

F1: Consists of an option granted on 3/1/2016 under the company's stock incentive plan as amended and restated.

F2: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F3: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20.

F4: Consists of an option granted on 2/28/2017 under the company's stock incentive plan as amended and restated.

F5: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.19.

F6: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.